Key Takeaway: The article discusses the results from the COG1201 study, which evaluated CT1812 in participants with mild-to-moderate dementia with Lewy bodies. The findings were presented at the International Lewy Body Dementia Conference in Amsterdam, highlighting the potential of CT1812 in this specific patient population. This proof-of-concept study contributes to ongoing research in dementia treatment.
Price reaction · baseline $0.6076 (2025-02-12 close) · hit pre-market · clean, no other CGTX news in the window
day 0 close
-2.9%
day 1
-2.9%
day 3
+3.7%
Market Sentiment Analysis
POSITIVE FACTORS
Presentation of promising results from a proof-of-concept study.
Focus on a specific patient population with mild-to-moderate dementia.
Engagement with the international research community at a notable conference.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
Galvin JE, Tolea MI, Fargo KN, et al. Results from COG1201: A Proof-of-Concept Study of CT1812 in Participants with Mild-to-Moderate Dementia with Lewy Bodies . Slides presented at International Lewy Body Dementia Conference (ILBDC) 2025; Amsterdam, The Netherlands
Frequently Asked Questions
What was the focus of the COG1201 study?
The COG1201 study focused on evaluating CT1812 in participants with mild-to-moderate dementia with Lewy bodies.
Where were the results of the study presented?
The results were presented at the International Lewy Body Dementia Conference in Amsterdam.
What type of study was COG1201?
COG1201 was a proof-of-concept study.
Who were the authors of the study results?
The study results were authored by Galvin JE, Tolea MI, Fargo KN, and others.